SEC Form 4 · accession 0001562180-15-000489
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Jonas
Officer — See Remarks · Director
Period of report
Jun 15, 2015
Accepted (ET)
Jun 17, 2015 · 3:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2015 | M | 83,374 | $0.45 | A | 89,374 | D | |
| Common StockF2 | Jun 15, 2015 | S | 1,554 | $83.8877 | D | 87,820 | D | |
| Common StockF3 | Jun 15, 2015 | S | 2,420 | $81.5066 | D | 85,400 | D | |
| Common StockF4 | Jun 15, 2015 | S | 5,707 | $79.9696 | D | 79,693 | D | |
| Common StockF5 | Jun 15, 2015 | S | 62,364 | $78.8775 | D | 17,329 | D | |
| Common StockF6 | Jun 15, 2015 | S | 11,329 | $78.2216 | D | 6,000 | D | |
| Common Stock | Jun 16, 2015 | M | 115,226 | $0.45 | A | 121,226 | D | |
| Common StockF7 | Jun 16, 2015 | S | 6,804 | $78.1261 | D | 114,422 | D | |
| Common StockF8 | Jun 16, 2015 | S | 14,146 | $76.8483 | D | 100,276 | D | |
| Common StockF9 | Jun 16, 2015 | S | 64,973 | $76.0886 | D | 35,303 | D | |
| Common StockF10 | Jun 16, 2015 | S | 29,303 | $75.5133 | D | 6,000 | D | |
| Common Stock | Jun 15, 2015 | M | 32,745 | $0.45 | A | 38,745 | D | |
| Common Stock | Jun 16, 2015 | M | 45,255 | $0.45 | A | 84,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F11 | $0.45 | Jun 15, 2015 | M | 128,629 | D | — | Aug 12, 2023 | Common Stock | 128,629 | 0 | D |
| Stock Option (Right to Buy)F11 | $0.45 | Jun 16, 2015 | M | 147,971 | D | — | Aug 12, 2023 | Common Stock | 147,971 | 0 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F10This transaction was executed in multiple trades at prices ranging from $75.50 USD to $75.55 USD. The price reported above reflects the weighted average sale price.
- F11The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option shall vest in full on August 12, 2017, subject to continued service through such date.
- F2This transaction was executed in multiple trades at prices ranging from $83.79 USD to $84.01 USD. The price reported above reflects the weighted average sale price.
- F3This transaction was executed in multiple trades at prices ranging from $80.64 USD to $81.63 USD. The price reported above reflects the weighted average sale price.
- F4This transaction was executed in multiple trades at prices ranging from $79.625 USD to $80.61 USD. The price reported above reflects the weighted average sale price.
- F5This transaction was executed in multiple trades at prices ranging from $78.58 USD to $79.58 USD. The price reported above reflects the weighted average sale price.
- F6This transaction was executed in multiple trades at prices ranging from $77.86 USD to $78.44 USD. The price reported above reflects the weighted average sale price.
- F7This transaction was executed in multiple trades at prices ranging from $77.60 USD to $78.595 USD. The price reported above reflects the weighted average sale price.
- F8This transaction was executed in multiple trades at prices ranging from $76.56 USD to $77.56 USD. The price reported above reflects the weighted average sale price.
- F9This transaction was executed in multiple trades at prices ranging from $75.555 USD to $76.555 USD. The price reported above reflects the weighted average sale price.